This 8-K filing discloses that Guggenheim and BofA Securities have significantly reduced their price targets for Twist Bioscience shares following the company's Q4 and full fiscal year 2026 financial results. This indicates a potentially negative re-evaluation of the company's future prospects by these financial institutions, likely due to the recently released earnings.
Guggenheim and BofA Securities have both lowered their price targets for Twist Bioscience (TWST) shares, with Guggenheim reducing its target from $212 to $150 and BofA from $205 to $150. These significant reductions, occurring on November 13, 2026, directly follow the company's release of its Q4 and full fiscal year 2026 financial results. This action suggests that the financial institutions found the recent earnings report to be disappointing or indicative of a weaker outlook than previously anticipated. For traders, this is a short-term negative signal, as reduced price targets can lead to downward pressure on the stock. Long-term implications depend on whether the underlying reasons for the target cuts are fundamental and persistent, or if the market has overreacted. The key risk for traders is further downside if other analysts follow suit or if the company's next earnings report doesn't show improvement.